Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Hedge fund Visium shuts one fund, sells another in wake of insider trading case

Published 06/17/2016, 09:37 PM
Updated 06/17/2016, 09:37 PM
© Reuters.  Hedge fund Visium shuts one fund, sells another in wake of insider trading case

By Svea Herbst-Bayliss

NEW YORK (Reuters) - Hedge fund Visium Asset Management, which has been embroiled in an insider trading case, told investors on Friday evening that it will close down its flagship fund and sell another portfolio to asset manager Alliance Bernstein.

Jacob Gottlieb, who founded the firm 11 years ago, disclosed the news in a letter just two days after the U.S. government charged a Visium partner with insider trading for having allegedly used confidential tips about drug regulatory approvals.

"Given the uncertainty relative to the final outcome of the recent regulatory developments, the negative impact of the resulting publicity, and the substantial investor withdrawals, it became clear that maintaining the status quo was increasingly untenable for the firm," Gottlieb wrote in the letter, which was seen by Reuters.

Visium expects to sell its Visium Global Fund to AllianceBernstein. Gottlieb said the fund's investment team and some support staff will move to the New York-based asset management firm, but that he will not be switching over.

Visium will be closing down its health-care-focused Visium Balanced Fund LP and related portfolios and told investors in the letter that they will be informed separately about details. To treat all investors fairly, the letter said that Visium would begin returning money to clients later this summer. But some money will be held back to "establish a reserve for possible liabilities and other contingencies," the letter said.

Federal officials on Wednesday arrested Sanjay Valvani, a Visium partner who focused on trading pharmaceutical stocks, and accused him of having fraudulently made $25 million by gaining advance word about U.S. Food and Drug Administration approvals of generic drug applications.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Valvani pleaded not guilty to five counts including securities fraud, wire fraud and conspiracy and was freed on $5 million bond secured by his home.

(with additional report by Jonathan Stempel, editing by Cynthia Osterman and Leslie Adler) OLUSMONEY Reuters US Online Report Money 20160617T234436+0000

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.